Evidence map›Paper›PMID 42028209›Full record

ArticleJournal of cancer metastasis and treatment2025

Perioperative therapies for metastatic renal cell carcinoma.

Matthew P Lierz, Allen Enrique D Siapno, Adam Khorasanchi, Shawn Dason, Yuanquan Yang, Eric A Singer

Abstract read
In one paragraph

Article in Journal of cancer metastasis and treatment, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Matthew P LierzDivision of Urologic Oncology, The Ohio State University Comprehensive Cancer Center, Columbus, OH 43221, USA.
Allen Enrique D SiapnoDivision of Urologic Oncology, The Ohio State University Comprehensive Cancer Center, Columbus, OH 43221, USA.
Adam KhorasanchiDivision of Medical Oncology, The Ohio State University Comprehensive Cancer Center, Columbus, OH 43221, USA.
Shawn DasonDivision of Urologic Oncology, The Ohio State University Comprehensive Cancer Center, Columbus, OH 43221, USA.
Yuanquan YangDivision of Medical Oncology, The Ohio State University Comprehensive Cancer Center, Columbus, OH 43221, USA.
Eric A SingerDivision of Urologic Oncology, The Ohio State University Comprehensive Cancer Center, Columbus, OH 43221, USA.

Funding

Translational Therapeutics Research Program (TT)P30CA016058 · NCI · OHIO STATE UNIVERSITY · PI Tasleem J Padamsee · 1985 to 2026
$132.3M
NCI NIH HHS P30 CA016058
6 · The paper itself

Abstract

Systemic therapy for metastatic renal cell carcinoma (mRCC) has advanced considerably over the past decade. Studies of systemic therapies in the adjuvant, neoadjuvant, and now perioperative settings as solitary, dual, and triplet combinations are underway. The timing of systemic therapy relative to extirpative surgery has yielded varying results. With the rise of novel therapeutics, new methods for risk stratification and patient selection, including initial biomarker evaluation, have begun. This perspective aims to summarize investigations into perioperative mRCC therapies and discuss the foundations of these concepts based on recent adjuvant and neoadjuvant trials, and to discuss future directions in this space.

Indexed as

adjuvantbiomarkersclinical trialscytoreductive nephrectomyimmune checkpoint inhibitorMetastatic renal cell carcinomaneoadjuvantperioperative therapytyrosine kinase inhibitor

Identifiers

PMID42028209
PMCPMC13102387

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.